Analyst Rating Update on Intercept Pharmaceuticals (ICPT)

Intercept Pharmaceuticals (NASDAQ:ICPT) has an average broker rating of 1.86, which is interpreted as a Buy, as rated by 12 equity analysts. Nonetheless, 8 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 2 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company. 1 considers that the stock is a Sell.

Intercept Pharmaceuticals (NASDAQ:ICPT) : Average target price received by Intercept Pharmaceuticals (NASDAQ:ICPT) is $205.82 with an expected standard deviation of $67.28. The most aggressive target on the stock is $332, whereas the most downbeat target is $80. 11 financial analysts are currently covering the stock.

For the current week, the company shares have a recommendation consensus of Buy. Also, Equity analysts at the Brokerage firm Cowen & Company maintains its rating on Intercept Pharmaceuticals (NASDAQ:ICPT). The rating major has initiated the coverage with outperform rating on the shares. The Analysts at Cowen & Company raises the price target from $212 per share to $215 per share. The rating by the firm was issued on May 31, 2016.

Intercept Pharmaceuticals (NASDAQ:ICPT): stock turned positive on Tuesday. Though the stock opened at $134.49, the bulls momentum made the stock top out at $154.31 level for the day. The stock recorded a low of $134 and closed the trading day at $149.37, in the green by 14.31%. The total traded volume for the day was 1,283,485. The stock had closed at $130.67 in the previous days trading.

In an insider trading activity, The Securities and Exchange Commission has divulged that Bright Lisa, officer (See Remarks) of Intercept Pharmaceuticals Inc, had unloaded 251 shares at an average price of $137.5 in a transaction dated on May 25, 2016. The total value of the transaction was worth $34,513.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Companys product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is also developing other products INT-767 and INT-777 for the treatment of fibrosis and type 2 diabetes. OCA has been tested in five placebo-controlled clinical trials, including a completed Phase III clinical trial in patients with primary biliary cirrhosis (PBC) and two Phase II clinical trials in patients with nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). OCA met the primary efficacy endpoint in each of these trials with statistical significance.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.